162 related articles for article (PubMed ID: 16638785)
1. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.
Singh-Grewal D; Kemp A; Wong M
Arch Dis Child; 2006 Aug; 91(8):651-4. PubMed ID: 16638785
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
[TBL] [Abstract][Full Text] [Related]
3. Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience.
Nain E; Kıykım A; Kasap NA; Barış S; Özen A; Aydıner EK
Turk J Pediatr; 2020; 62(3):379-386. PubMed ID: 32558411
[TBL] [Abstract][Full Text] [Related]
4. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
5. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
6. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
Tcheurekdjian H; Martin J; Kobayashi R; Wasserman R; Hostoffer R
Allergy Asthma Proc; 2006; 27(6):532-6. PubMed ID: 17176791
[TBL] [Abstract][Full Text] [Related]
7. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.
Kaba S; Keskindemirci G; Aydogmus C; Siraneci R; Erol Cipe F
Eur Ann Allergy Clin Immunol; 2017 Jan; 49(1):11-14. PubMed ID: 28120600
[TBL] [Abstract][Full Text] [Related]
8. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
[TBL] [Abstract][Full Text] [Related]
9. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
10. Decreased incidence of adverse infusion reactions in hypogammaglobulinemic children receiving low pH intravenous immunoglobulin.
Roberton DM; Hosking CS; Efthimiou H; Wright S; Upton H; Colgan T; Hartman L; Schiff P
Aust N Z J Med; 1987 Oct; 17(5):495-500. PubMed ID: 3446162
[TBL] [Abstract][Full Text] [Related]
11. [Adverse events in 1395 infusions with different intravenous gammaglobulin products].
Malbrán A; Larrauri B; Juri MC; Fernández Romero DS
Medicina (B Aires); 2013; 73(5):433-7. PubMed ID: 24152399
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.
Ochs HD; Melamed I; Borte M; Moy JN; Pyringer B; D Kobayashi AL; Knutsen AP; Smits W; Pituch-Noworolska A; Kobayashi RH
Immunotherapy; 2018 Oct; 10(14):1193-1202. PubMed ID: 30088423
[TBL] [Abstract][Full Text] [Related]
16. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
[TBL] [Abstract][Full Text] [Related]
17. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
18. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.
Kallenberg CG
Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584
[TBL] [Abstract][Full Text] [Related]
19. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.
Brennan VM; Salomé-Bentley NJ; Chapel HM;
Clin Exp Immunol; 2003 Aug; 133(2):247-51. PubMed ID: 12869031
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]